BioNTech to Build Covid-19 Vaccine Facility in Singapore By 2023

Inside BioNTech SE's New Vaccine Laboratory As Target Raised to 2.5 Billion Doses — Photographer: Cyril Marcilhacy/Bloomberg

Have a confidential tip for our reporters? Get in Touch

Before it’s here, it’s on the Bloomberg Terminal

May 10, 2021 at 2:30 AM EDT

This article is for subscribers only.

German vaccine developer BioNTech SE selected Singapore as its Southeast Asia headquarters and first Asia-Pacific hub, giving a boost to supply of an mRNA vaccine that’s been extraordinarily effective in fighting Covid-19.

The production site could be operational as early as 2023 and will create as many as 80 jobs in Singapore, the company said in a statement Monday.

Have a confidential tip for our reporters? Get in Touch

Before it’s here, it’s on the Bloomberg Terminal

LEARN MORE